A novel cholic acid analog which acts as a potent and selective FXR agonist (EC50= 99 nM). Displays anticholeretic activity in a rat model of cholestasis. Promotes adipocyte differentiation and regulates adipose cell function. A potentially new therapeutic agent for management of non-alcoholic...
Know who made it. See the evidence. Buy through one marketplace.
A novel cholic acid analog which acts as a potent and selective FXR agonist (EC50= 99 nM). Displays anticholeretic activity in a rat model of cholestasis. Promotes adipocyte differentiation and regulates adipose cell function. A potentially new therapeutic agent for management of non-alcoholic fatty liver disease and NASH. Displays therapeutic benefit in patients with primary biliary cirrhosis. Active in vivo
This product is manufactured by TriBio Science and sold through ABMIUM without relabelling.
ABMIUM supports global orders. Availability, shipping requirements and applicable import arrangements are confirmed before fulfilment where required.
Yes. Send your target, sample, application and experimental conditions through ABMIUM MATCH or technical support.
Unless the listing expressly states otherwise, ABMIUM products are supplied for research use only and are not for diagnostic or therapeutic use.
